BriaCell Therapeutics Corp. announced initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS?, BriaCell?s personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor tislelizumab, in advanced metastatic breast cancer. Awarded numerous US and international patents and supported by clinical data of Bria-IMT?, BriaCell?s lead clinical candidate - currently in a pivotal Phase 3 study for advanced metastatic breast cancer (ClinicalTrials.gov NCT06072612), Bria-OTS?

is BriaCell?s personalized off-the-shelf immunotherapy platform, and the basis for BriaCell?s ?OTS? strategy. Bria-OTS?

for advanced metastatic breast cancer is the first use of this platform. Similar cell lines are in development for prostate cancer (Bria-PROS+?), lung cancer (Bria-LUNG+?), and melanoma (Bria-MEL+?). An Investigational New Drug Application (IND) is currently open for the Bria-OTS?

breast cancer therapy also known as, Bria-BRES? for advanced metastatic breast cancer. Bria-BRES?

will initiate a bucket trial (i.e. a study that investigates multiple product candidates in a single study) with other cancer indications. Bria-OTS? received a Small Business Innovation Research (SBIR) award from the National Cancer Institute (NCI).